DTC Brief Summary: Consumers Prefer Q&A Format, Researcher Tells FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
University of Georgia professor says consumers reacted negatively to use of a prominent risk information window in print ads. FDA ad division official questions whether a drug’s efficacy information should be included in the brief summary.
You may also be interested in...
GSK/Roche's Boniva Print Ad Uses Question-And-Answer Brief Summary
Print campaign for the osteoporosis agent uses a reprint of the patient information sheet, which is in a Q&A format, instead of traditional brief summary format. The campaign highlights Boniva's unique once-monthly dosing regimen.
GSK/Roche's Boniva Print Ad Uses Question-And-Answer Brief Summary
Print campaign for the osteoporosis agent uses a reprint of the patient information sheet, which is in a Q&A format, instead of traditional brief summary format. The campaign highlights Boniva's unique once-monthly dosing regimen.
FDA Finalizing Study Protocols For DTC Ad Brief Summary Research
In the first of three studies, FDA will examine consumer responses to a mock weight-loss drug ad to determine how and why consumers use the brief summary. Research data will be collected in the spring, but a final guidance on the brief summary content and format “will be awhile,” FDA says.